Literature DB >> 16537514

Targeted covalent inactivation of protein kinases by resorcylic acid lactone polyketides.

Andreas Schirmer1, Jonathan Kennedy, Sumati Murli, Ralph Reid, Daniel V Santi.   

Abstract

Resorcylic acid lactones containing a cis-enone are susceptible to Michael addition reactions and are potent inhibitors of several protein kinases. A structural-bioinformatics analysis identified a conserved Cys residue in the ATP-binding site of the kinases reported to be inhibited by cis-enone resorcylic acid lactones but absent in those that are not. Mining of the kinome database revealed that a subset of some 46 kinases contained this Cys residue. Screening a panel of 124 kinases with the resorcylic acid lactone hypothemycin showed that 18 of 19 targets containing the conserved Cys were inhibited. Kinetic analyses showed time-dependent inhibition, a hallmark of covalent inactivation, and biochemical studies of the interaction of extracellular signal-regulated kinase (ERK)2 with hypothemycin confirmed covalent adduct formation. Resorcylic acid lactones are unique among kinase inhibitors in that they target mitogen-activated protein (MAP) kinase pathways at four levels: mitogen receptors, MAP kinase kinase (MEK)1/2 and ERK1/2, and certain downstream ERK substrates. Cell lines dependent on the activation of Tyr kinase mitogen receptor targets of the resorcylic acid lactones were unusually sensitive toward hypothemycin and showed the expected inhibition of kinase phosphorylation due to inhibition of the mitogen receptors and/or MEK1/2 and ERK1/2. Among cells without mitogen receptor targets, those harboring an ERK pathway-activating B-RAF V600E mutation were selectively and potently inhibited by hypothemycin. Hypothemycin also prevented stimulated activation of the p38 cascade through inhibition of the Cys-containing targets MEK3/6 and TGF-beta-activated kinase 1 and of the JNK/SAPK (c-Jun N-terminal kinase/stress-activated protein kinase) cascade through inhibition of MEK4/7.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16537514      PMCID: PMC1449676          DOI: 10.1073/pnas.0600445103

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  26 in total

1.  Production of a family of kinase-inhibiting lactones from fungal fermentations.

Authors:  A Dombrowski; R Jenkins; S Raghoobar; G Bills; J Polishook; F Peláez; B Burgess; A Zhao; L Huang; Y Zhang; M Goetz
Journal:  J Antibiot (Tokyo)       Date:  1999-12       Impact factor: 2.649

2.  Hypothemycin inhibits the proliferative response and modulates the production of cytokines during T cell activation.

Authors:  R Camacho; M J Staruch; C DaSilva; S Koprak; T Sewell; G Salituro; F J Dumont
Journal:  Immunopharmacology       Date:  1999-11

Review 3.  Features of selective kinase inhibitors.

Authors:  Zachary A Knight; Kevan M Shokat
Journal:  Chem Biol       Date:  2005-06

4.  A small molecule-kinase interaction map for clinical kinase inhibitors.

Authors:  Miles A Fabian; William H Biggs; Daniel K Treiber; Corey E Atteridge; Mihai D Azimioara; Michael G Benedetti; Todd A Carter; Pietro Ciceri; Philip T Edeen; Mark Floyd; Julia M Ford; Margaret Galvin; Jay L Gerlach; Robert M Grotzfeld; Sanna Herrgard; Darren E Insko; Michael A Insko; Andiliy G Lai; Jean-Michel Lélias; Shamal A Mehta; Zdravko V Milanov; Anne Marie Velasco; Lisa M Wodicka; Hitesh K Patel; Patrick P Zarrinkar; David J Lockhart
Journal:  Nat Biotechnol       Date:  2005-02-13       Impact factor: 54.908

5.  Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma.

Authors:  Levi A Garraway; Hans R Widlund; Mark A Rubin; Gad Getz; Aaron J Berger; Sridhar Ramaswamy; Rameen Beroukhim; Danny A Milner; Scott R Granter; Jinyan Du; Charles Lee; Stephan N Wagner; Cheng Li; Todd R Golub; David L Rimm; Matthew L Meyerson; David E Fisher; William R Sellers
Journal:  Nature       Date:  2005-07-07       Impact factor: 49.962

6.  BRAF mutation predicts sensitivity to MEK inhibition.

Authors:  David B Solit; Levi A Garraway; Christine A Pratilas; Ayana Sawai; Gad Getz; Andrea Basso; Qing Ye; Jose M Lobo; Yuhong She; Iman Osman; Todd R Golub; Judith Sebolt-Leopold; William R Sellers; Neal Rosen
Journal:  Nature       Date:  2005-11-06       Impact factor: 49.962

7.  Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib.

Authors:  Eunice L Kwak; Raffaella Sordella; Daphne W Bell; Nadia Godin-Heymann; Ross A Okimoto; Brian W Brannigan; Patricia L Harris; David R Driscoll; Panos Fidias; Thomas J Lynch; Sridhar K Rabindran; John P McGinnis; Allan Wissner; Sreenath V Sharma; Kurt J Isselbacher; Jeffrey Settleman; Daniel A Haber
Journal:  Proc Natl Acad Sci U S A       Date:  2005-05-16       Impact factor: 11.205

8.  Structural bioinformatics-based design of selective, irreversible kinase inhibitors.

Authors:  Michael S Cohen; Chao Zhang; Kevan M Shokat; Jack Taunton
Journal:  Science       Date:  2005-05-27       Impact factor: 47.728

9.  Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor.

Authors:  D W Fry; A J Bridges; W A Denny; A Doherty; K D Greis; J L Hicks; K E Hook; P R Keller; W R Leopold; J A Loo; D J McNamara; J M Nelson; V Sherwood; J B Smaill; S Trumpp-Kallmeyer; E M Dobrusin
Journal:  Proc Natl Acad Sci U S A       Date:  1998-09-29       Impact factor: 11.205

10.  Antitumor efficacy of hypothemycin, a new Ras-signaling inhibitor.

Authors:  H Tanaka; K Nishida; K Sugita; T Yoshioka
Journal:  Jpn J Cancer Res       Date:  1999-10
View more
  47 in total

1.  Total synthesis of LL-Z1640-2 utilizing a late-stage intramolecular Nozaki-Hiyama-Kishi reaction.

Authors:  Christopher A Leclair; Matthew B Boxer; Craig J Thomas; David J Maloney
Journal:  Tetrahedron Lett       Date:  2010-12-29       Impact factor: 2.415

2.  A computational workflow for the design of irreversible inhibitors of protein kinases.

Authors:  Alberto Del Rio; Miriam Sgobba; Marco Daniele Parenti; Gianluca Degliesposti; Rosetta Forestiero; Claudia Percivalle; Pier Franco Conte; Mauro Freccero; Giulio Rastelli
Journal:  J Comput Aided Mol Des       Date:  2010-03-21       Impact factor: 3.686

Review 3.  Targeting cancer with small molecule kinase inhibitors.

Authors:  Jianming Zhang; Priscilla L Yang; Nathanael S Gray
Journal:  Nat Rev Cancer       Date:  2009-01       Impact factor: 60.716

4.  Characterization and optimization of a red-shifted fluorescence polarization ADP detection assay.

Authors:  Karen M Kleman-Leyer; Tony A Klink; Andrew L Kopp; Thane A Westermeyer; Mark D Koeff; Brad R Larson; Tracy J Worzella; Cori A Pinchard; Sebastianus A T van de Kar; Guido J R Zaman; Jorrit J Hornberg; Robert G Lowery
Journal:  Assay Drug Dev Technol       Date:  2009-02       Impact factor: 1.738

Review 5.  Enzymatic chemistry of cyclopropane, epoxide, and aziridine biosynthesis.

Authors:  Christopher J Thibodeaux; Wei-chen Chang; Hung-wen Liu
Journal:  Chem Rev       Date:  2011-10-21       Impact factor: 60.622

6.  An allosteric kinase inhibitor binds the p21-activated kinase autoregulatory domain covalently.

Authors:  Julien Viaud; Jeffrey R Peterson
Journal:  Mol Cancer Ther       Date:  2009-09-01       Impact factor: 6.261

7.  Genes for the biosynthesis of the fungal polyketides hypothemycin from Hypomyces subiculosus and radicicol from Pochonia chlamydosporia.

Authors:  Christopher D Reeves; Zhihao Hu; Ralph Reid; James T Kealey
Journal:  Appl Environ Microbiol       Date:  2008-06-20       Impact factor: 4.792

8.  Evaluating PI3 kinase isoforms using Transcreener ADP assays.

Authors:  Tony A Klink; Karen M Kleman-Leyer; Andrew Kopp; Thane A Westermeyer; Robert G Lowery
Journal:  J Biomol Screen       Date:  2008-06-19

9.  Development of a high-throughput cell-based reporter assay to identify stabilizers of tumor suppressor Pdcd4.

Authors:  Johanna S Blees; Tobias Schmid; Cheryl L Thomas; Alyson R Baker; Lauren Benson; Jason R Evans; Ekaterina I Goncharova; Nancy H Colburn; James B McMahon; Curtis J Henrich
Journal:  J Biomol Screen       Date:  2009-11-09

10.  Arylfluorosulfates Inactivate Intracellular Lipid Binding Protein(s) through Chemoselective SuFEx Reaction with a Binding Site Tyr Residue.

Authors:  Wentao Chen; Jiajia Dong; Lars Plate; David E Mortenson; Gabriel J Brighty; Suhua Li; Yu Liu; Andrea Galmozzi; Peter S Lee; Jonathan J Hulce; Benjamin F Cravatt; Enrique Saez; Evan T Powers; Ian A Wilson; K Barry Sharpless; Jeffery W Kelly
Journal:  J Am Chem Soc       Date:  2016-06-02       Impact factor: 15.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.